Vanda Pharmaceuticals | VNDA - Current Liabilities


Vanda Pharmaceuticals reported $145.16M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
J&J USD 54.9B 2.82B Jun/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Moderna USD 2.4B 408M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Takeda JPY 2.43T 180.65B Mar/2026
Teva Pharmaceutical Industries USD 13.53B 76M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Veracyte USD 56.11M 3.82M Mar/2026